《新股消息》微創醫療(00853.HK)就分拆微創心律管理提交主板上市申請
微創醫療(00853.HK)宣布擬分拆持股50.13%的微創心律管理於聯交所主板上市,聯席保薦人為高盛及中金公司。
初步招股文件顯示,微創心律管理是處於商業階段醫療技術公司,專注於心律管理(CRM)有源植入式醫療器械,目前於三大洲進行研發及製造,並在全球49個國家及地區銷售產品,除西歐、日本、澳洲及美國等成熟CRM器械市場外,亦正進軍巴西、印度及阿根廷等新興市場。
去年度公司錄得2.05億美元收入,按年跌6.9%,經營虧損達6,864.4萬美元,年內虧損則擴大至近1.07億美元,對比2021年度虧損8,806.3萬美元。公司解釋,主要是由於收入減少及融資成本增加,當中有部分被銷售成本減少所抵銷。
公司預期上市集資所得款項將用於研發在研產品、產品商業化,以及重組於法國、意大利、中國及多米尼加共和國的四間生產設施等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.